2Año·

Healthcare sector thus also covered and most convinced by J&J🙈🐵

10.09

Johnson&Johnson

Compró 7 a 152,56 €

1067,94 €

5 Comentarios

Tojasoku@Tojasoku

2Año

For what reason J&J?

•

DividendenAffe@Jico

2Año

J&J had a strong correction has now recovered already 2% divi + strong growth in my eyes and in my opinion they have no more hurdles ahead of them in the near future and will grow solidly. Novo nordisk & CVS health were still in the selection...

••

Tojasoku@Tojasoku

2Año

@Jico Have you looked further into the products? It's always interesting to see what's in the pipeline, especially with pharmaceuticals.

••

Ver una respuesta más

Chris@Psychedelic_Sunflower

2Año

Not every sector has to be covered. Pharma is difficult. You either have to be able to assess the pipeline quite well and still move in highly speculative spheres or you have enormously sporty valued companies in front of your nose or, as in the case of Johnson & Johnson, a blue chip portfolio brake with only moderate growth and the constant danger of slipping into some pharmaceutical scandal.

•

Peace@Pinkafeld

2Año

J&j falls. Abott and Amgen are more stable

••